Pharma News

International Society for Pharmacoeconomics and Outcomes Research ISPOR India –Andhra Pradesh Regional Chapter in association with Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh; Rural Development Trust (RDT) Hospital, Anantapuramu, Andhra Pradesh and Indian Pharmaceutical Association (IPA) Anantapuramu Local Branch organized One Day National Symposium on “Innovations in Pharmacovigilance for ensuring Drug Safety and ensuring Life” on 24th November 2016 (Thursday)  at A.C auditorium, Rural Development Trust (RDT) Hospital, Anantapuramu, Andhra Pradesh.

Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh in association with Priyadarshini Institute of Pharmaceutical Education and Research, Guntur. Andhra Pradesh organized a Two Days National Workshop on Advances in Pharmacy Practice: Series of Educational and Training Module by faculties of Division of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER).  The workshop drew around 60 Pharm. D students, which focussed on Patient care and the role of Pharmacists in healthcare system on policy and practice perspective.

[adsense:336x280:8701650588]

Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is US$ 24 million. Sun Pharma would also assume a debt of approximately US$ 36 million as part of this transaction.

Proteros biostructures GmbH announced that the company has entered into a second research agreement with Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, USA (known as MSD outside the US and Canada). The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy® 100/3.6. Xultophy® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).

Janssen-Cilag International NV announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis. Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development of immune-mediated inflammatory diseases.

Eli Lilly and Company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale).

GlaxoSmithKline plc announced that both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study investigating the efficacy and safety of mepolizumab, an IL-5 antagonist, in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare disease characterised by widespread inflammation in the walls of small blood vessels (vasculitis).

GlaxoSmithKline plc and Innoviva, Inc. announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD). This follows the announcement earlier this year of plans to bring forward the timing of the US filing from the first half of 2018.

GlaxoSmithKline plc announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).
The phase III programme includes two studies evaluating the safety and efficacy of daprodustat compared to recombinant human erythropoietin